Israeli health tech thrives amid global challenges, attracting $1.2 billion in 2024
Israeli health tech thrives amid global challenges, attracting $1.2 billion in 2024
From AI-driven diagnostics to cutting-edge medical devices, Israeli companies are paving the way in health innovation.
Israel's health tech sector remained resilient in 2024, securing $1.2 billion in private funding despite ongoing global economic challenges. The Health Tech Top 100 map, compiled by Startup Nation Central’s Finder platform, underscores Israel’s key role in biopharma, digital health, and medical devices.
While total funding decreased slightly from $1.6 billion in 2023, the sector saw a notable increase in the average deal size, which reached $4.6 million across 102 funding rounds—more than double the previous year’s median of $2.16 million. Digital health emerged as the leading sector, attracting $545 million, followed by medical devices ($380 million) and pharma/biotech ($262 million).
Significant investments included $150 million raised by Insightec for its MRI-guided focused ultrasound technology, and $111 million secured by VI Labs for its AI-powered healthcare solutions. Magenta Medical received $105 million to advance its heart failure treatment innovations, while Exsilio Therapeutics raised $82 million for its genomic medicine research.
Early-stage startups also secured substantial funding, such as AISAP, which raised $13 million to develop AI-powered ultrasound technology, and Promise Bio, which received $8.3 million to advance precision medicine.
Multinational corporations continued to play a pivotal role in Israel’s health tech ecosystem, with key acquisitions such as Innovalve Bio Medical by Edwards Lifesciences and V-Wave by Johnson & Johnson. CytoReason, an AI-driven precision medicine company, raised $80 million in Series C funding from NVIDIA, Pfizer, and Thermo Fisher, further solidifying Israel’s global influence in health tech.
